发布求助
文献互助 智能选刊 最新文献

Cancer clinical trials最新文献

筛选
英文 中文
Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. 强的松对骨髓瘤维持方案的评价。阿霉素、木脲和长春新碱在小鼠浆细胞瘤模型中的作用。
Cancer clinical trials Pub Date : 1981-01-01
V K Ghanta, H J Cohen, H R Silberman, J R Durant, R N Hiramoto
{"title":"Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.","authors":"V K Ghanta,&nbsp;H J Cohen,&nbsp;H R Silberman,&nbsp;J R Durant,&nbsp;R N Hiramoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A current southeastern cancer study group protocol for the treatment of multiple myeloma involves induction with BCNU, cyclophosphamide, and prednisone (BCP) and maintenance with either melphalan and prednisone (MP), prednisone, Adriamycin, imuran, and vincristine (PAIV), or delayed treatment of relapsed cases following induction. These combinations of drugs are used as induction regimens to establish their chemotherapeutic effects and hematological toxicity in the murine MOPC 104E plasmacytoma model. The three combinations of drugs produce rapid, reliable, and reproducible tumor regressions. However, MP is the only combination which consistently gives long-term disease-free survivors. This particular regimen has least toxicity and is considered to be most effective. BCP produces complete remission with no relapses; however, long-term survivors are not observed with this combination due to early deaths because of drug toxicity. Most of the mice on the PAIV regimen die due to drug toxicity. This combination is considered least effective. With the different drug regimens, toxic events and regressions are noted to occur at different time periods, indicating that perhaps tumor cells in different stages are being destroyed. Toxic events as measured by hematocrit and body weight changes always precede regression by several days. This disparity between rapid drug effects on the host and a delayed effect on the tumor remains unexplained but may possibly be used to advantage in designing future trials.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"135-41"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18263276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of dihydroxyanthraquinone and radiation on L1210 murine leukemia. 二羟基蒽醌联合辐射治疗L1210小鼠白血病。
Cancer clinical trials Pub Date : 1981-01-01
B F Kimler, M P Hacker
{"title":"Combination of dihydroxyanthraquinone and radiation on L1210 murine leukemia.","authors":"B F Kimler,&nbsp;M P Hacker","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A new synthetic anthraquinone, dihydroxyanthraquinone (DHAQ), was tested as a single agent and in combination with whole-body x-irradiation in mice bearing L1210 leukemia in the ascites form. DHAQ alone had significant antitumor activity as evidenced by prolonged mean survival times; radiation was ineffective. The combination of the two modalities produced a therapeutic benefits greater than that produced by either agent alone: mean survival times were increased and a number of cures (animals alive at 30 days) produced. These results suggest the potential of using DHAQ and radiation in a combined modality therapeutic approach.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"173-6"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18263280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Summary of workshop on present knowledge of late effects of treatment on endocrine function. 治疗对内分泌功能的晚期影响的现有知识研讨会综述。
Cancer clinical trials Pub Date : 1981-01-01
C Sklar, M Nesbit
{"title":"Summary of workshop on present knowledge of late effects of treatment on endocrine function.","authors":"C Sklar,&nbsp;M Nesbit","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 Suppl ","pages":"21-3"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18319552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term effects - immunohematopoietic workshop. 长期效果-免疫造血车间。
Cancer clinical trials Pub Date : 1981-01-01
C A Perez, P B Chrétien
{"title":"Long-term effects - immunohematopoietic workshop.","authors":"C A Perez,&nbsp;P B Chrétien","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 Suppl ","pages":"61-71"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18319556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An alternative model for the evaluation of antitumor activity. 另一种评估抗肿瘤活性的模型。
Cancer clinical trials Pub Date : 1981-01-01
P T Lavin
{"title":"An alternative model for the evaluation of antitumor activity.","authors":"P T Lavin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To date, in cancer clinical trials, treatment programs have been evaluated using objective tumor response as the primary means to demonstrate antitumor activity. This measure, which is based upon a dichotomous outcome whether or not a 50% decrease in tumor area has occurred, is complemented by the alternative measure of the distribution of the ratio of the tumor area taken at a fixed time point compared to the tumor area at the start of protocol treatment. It is inferred that the distribution of the tumor area ratio obeys a log-normal distribution for advanced gastric cancer and that this result may hold for many advanced measurable cancer studies. The identification of this distribution allows for the evaluation of treatment programs using parametric tests. In situations where log-normality does not apply, a Normal Scores test is recommended. This concept may be applied to completed studies to gain additional perspective regarding antitumor activity. A marked reduction in sample size requirements can be achieved when the tumor area ratio is used as a study design criteria. This approach is especially recommended in the phase II setting.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"451-7"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ICRF-187 in clinical oncology. 临床肿瘤学的ICRF-187。
Cancer clinical trials Pub Date : 1981-01-01
D S Poster, J S Penta, S Bruno, J S Macdonald
{"title":"ICRF-187 in clinical oncology.","authors":"D S Poster,&nbsp;J S Penta,&nbsp;S Bruno,&nbsp;J S Macdonald","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Although the mechanism of action of ICRF-159 and 187 has not been clearly defined, it is evident from both preclinical and early clinical studies that these compounds are of interest. There are three distinct characteristics of these ICRF compounds that deserve careful clinical evaluation. First, these drugs are apparently alkylating agents with modest, predictable and noncumulative bone marrow toxicity that makes them good potential candidates for combination chemotherapy regimens. The second characteristic that should be investigated is the suggestion that combination of ICRF-187 with an anthracycline may ameliorate the cardiac toxicity of the latter. The third factor in the preclinical evaluation of the bis-diketopiperazines that may have clinical application is the evidence that suggests that these drugs have an antimetastatic effect.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"143-6"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17840557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective validation of a new staging system for Wilms' tumor. 一种新的肾母细胞瘤分期系统的回顾性验证。
Cancer clinical trials Pub Date : 1981-01-01
V T Farewell, G J D'Angio, N Breslow, P Norkool
{"title":"Retrospective validation of a new staging system for Wilms' tumor.","authors":"V T Farewell,&nbsp;G J D'Angio,&nbsp;N Breslow,&nbsp;P Norkool","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prognostic significance has been ascribed to certain clinicopathological features of the Wilms' tumor. Examples are size, vascular invasion, histologic characteristics, tumor rupture, and lymph nodal involvement. Several of these were arranged into a grouping system, and used in a cooperative clinical trial, the first National Wilms' Tumor Study (NWTS). Detailed clinicopathologic information was accumulated for each patient entered in the study, and these data were analyzed with respect to their prognostic import. Factors found to be of significance were rearranged into a proposed staging system, believed more likely to be predictive of outcome for patients with tumor spread beyond the kidney confines, but without distant metastases (Groups II and III). The postulated discriminatory superiority was tested using Group II and III patients entered in the second NWTS. The same children were reassigned retrospectively to Stages II and III, and the outcomes compared. Statistically significant differences were noted between Stages II and III, but not for Groups II and III. These results encourage the use of the new staging system in the third NWTS.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"167-71"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17327548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chlorozotocin (DCNU)--induced pulmonary toxicity. 氯佐菌素(DCNU)-诱导肺毒性。
Cancer clinical trials Pub Date : 1981-01-01
E M Sordillo, P P Sordillo, D Stover, G B Magill
{"title":"Chlorozotocin (DCNU)--induced pulmonary toxicity.","authors":"E M Sordillo,&nbsp;P P Sordillo,&nbsp;D Stover,&nbsp;G B Magill","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A case of pulmonary toxicity after chlorozotocin (DCNU) is described. This patient developed shortness of breath, nonproductive cough, and interstitial infiltrates after his third dose of DCNU. This was documented on pulmonary function tests which showed a reduction in vital capacity and pulmonary diffusion capacity. Similar findings have been reported in restrictive pulmonary disease associated with other nitrosoureas. This is the first case reported of pulmonary toxicity induced by DCNU.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"397-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17518046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of x-irradiation on immunocompetency of T-lymphocytes. x射线照射对t淋巴细胞免疫能力的影响。
Cancer clinical trials Pub Date : 1981-01-01
C W Song, J G Rhee, T Kim, J H Kersey, S H Levitt
{"title":"Effect of x-irradiation on immunocompetency of T-lymphocytes.","authors":"C W Song,&nbsp;J G Rhee,&nbsp;T Kim,&nbsp;J H Kersey,&nbsp;S H Levitt","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Effect of x-irradiation on various aspects of cell-mediated immune reactions is studied. The irradiated splenic lymphocytes could transform to blast cells upon stimulation with PHA, but could not divide into small lymphocytes. It was concluded that irradiation at doses higher than 500 rads inhibits the differentiation of lymphocytes to effector cells upon stimulation with antigens. The irradiated immune lymphocytes were able to kill target tumor cells when the cytotoxicity was tested immediately after irradiation with doses as high as 500 rads. The cytotoxicity of immune lymphocytes diminished, however, 7--10 hours after irradiation. The splenic lymphocytes irradiated with doses as high as 200 rads could stimulate allogeneic lymphocytes 2 days after the irradiation. It thus appeared that irradiation cannot immediately abolish the antigenicity of lymphocytes to stimulate allogeneic lymphocytes. The combined effect of irradiation and T-cell-mediated immune reaction to reduce clonogenecity of target tumor cells in vitro is simple additive.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"331-42"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18024007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study. 晚期复发何杰金氏病的MER免疫治疗和联合化疗。癌症和白血病B组研究。
Cancer clinical trials Pub Date : 1981-01-01
V Vinciguerra, M Coleman, T F Pajak, S Rafla, L Stutzman, G Gomez, M Weil, K Brunner, J Cuttner, N Nissen, B Leventhal, A Gottlieb
{"title":"MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study.","authors":"V Vinciguerra,&nbsp;M Coleman,&nbsp;T F Pajak,&nbsp;S Rafla,&nbsp;L Stutzman,&nbsp;G Gomez,&nbsp;M Weil,&nbsp;K Brunner,&nbsp;J Cuttner,&nbsp;N Nissen,&nbsp;B Leventhal,&nbsp;A Gottlieb","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The effects of chemotherapy and chemoimmunotherapy in previously treated advanced Hodgkin's disease were evaluated in a randomized study of 167 patients by CALGB. Combination chemotherapy consisted of treatment with one of three regimens with further randomization of MER (methanol extraction residue BCG) immunotherapy or no MER during chemotherapy. CVPP (CCNU, vinblastine, procarbazine, prednisone) was compared to a new combination, BAVS (bleomycin, Adriamycin, vincristine, streptozotocin), and to a third regimen consisting of alternating cycles of CVPP and BAVS. At the current analysis there is no significant difference in complete responses among the chemotherapy regimens. MER did not improve complete response frequency and was associated with significantly poorer survival for patients previously treated with chemotherapy. There was also no benefit with MER for patients with at least one pretreatment positive skin test. Because of the documented lack of therapeutic benefit and the morbidity of painful ulcers, MER treatment has been discontinued.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"99-105"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18067113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信